Ruperto N, Brunner HI, Ramanan AV, et al. - In two 52-week phase 1 b trials, researchers sought to determine subcutaneous-tocilizumab (SC-TCZ) dosing regimens for systemic juvenile idiopathic arthritis (sJIA) and polyarticular JIA (pJIA). SC-TCZ (162 mg/dose) was administered to patients with sJIA every week or every 2 weeks (every 10 days prior to interim analysis) and to patients with pJIA every 2 weeks or every 3 weeks with bodyweight ≥ 30 kg or < 30 kg, respectively. Participants in the study were 51 sJIA patients and 52 pJIA patients aged 1–17 years who received SC-TCZ. Pharmacodynamic markers of disease were comparable between body weight groups in both populations. Exposure and risk/benefit profiles similar to those of IV-TCZ are given by SC-TCZ. Subcutaneous administration offers an alternative route of administration that is more convenient and has the potential for in-home use for patients and caregivers.